Phase 4 N=168 Treatment of Severe Childhood Aggression (The TOSCA Study)
Attention Deficit Disorder With Hyperactivity
Primary: NCBRF-TIQ D-Total Score — 43.5; 42.1; 24.9; 25.9 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Pheochromocytoma · Paraganglioma
Primary: MTD of Ultratrace Iobenguane I 131 — 8 mCi/kg
Phase 3 N=346 The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) — -0.99; -0.07 percentage of glycosylated haemoglobin
Phase 2 N=40 Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Primary: Number of Participants With Drug-related Adverse Events (AEs) of Grade 3 or Higher — 20 Participants
N/A N=30 Aspiration of Limited Number of Follicles to Prevent Severe Ovarian Hyperstimulation Syndrome
Infertility
Primary: Number of Participants of Severe Ovarian Hyperstimulation Syndrome — 2; 11 participants
N/A N=17 Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains
Port Wine Stains
Primary: Blanching of Port Wine Stain Birthmark — 16 participants
N/A N=10 A Feasibility Study for Growth Bone Vertically With Titanium Mesh and Allograft in Lower Posterior Jaw
Alveolar Bone Loss
Primary: Bone Height — 12.2 millimeters
Phase 4 N=97 Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: SKAMP-Combined Scores — 10.0; 17.8 units on a scale — p=<0.0001
Phase 3 N=4,312 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Primary Peritoneal Carcinoma · Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Overall Survival — 0.35; 0.34; 0.39; 0.34 Proportion of participants
N/A N=60 Clinical Performance of Habitual Hydrogel vs. Silicone Hydrogel Toric Contact Lenses
Astigmatism
Primary: Participant's Subjective Rating for Lens Initial Comfort — 6.9; 7.4; 8.0; 8.9 units on a scale
Phase 1 N=44 Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
Solid Tumours
Primary: Cmax of Olaparib — 7.227; 9.081; 9.977 μg/mL
Phase 1 N=57 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients
Hepatitis C, Chronic
Primary: Number of Participants With Virologic Response Defined as >= 3 Log Drop in Viral Load From Baseline at Day 28 With no Evidence of Virologic Rebound During These 28 Days…
N/A N=265 Type 3 Von Willebrand International Registries Inhibitor Prospective Study
Type 3 Von Willebrand's Disease
Primary: Centralized Factor VIII (FVIII) Procoagulant Activity (FVIII:C) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis — 2.42 IU/dL
Phase 3 N=100 Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses
Actinic Keratoses
Primary: Lesion Response — 89.2; 92.8 percentage of lesions complete response — p=0.0345
Phase 3 N=60 Analgesic Efficacy of Repeated Doses of Intravenous (IV) Acetaminophen in Post-operative Pediatric Spine Fusion Patients
Pain, Postoperative
Primary: Total Opiate Requirement — 1.19; 1.01 mg/kg